

REMARKS

Applicants now respond to the Office Action (Restriction Requirement) mailed February 7, 2007. The Examiner required restriction to one of the following groups of claims under PCT Rules 13.1 and 13.2:

Group 1: Claim 7, allegedly “drawn to a method of screening agents for promoting insulin production or insulin content;”

Group 2: Claim 8, allegedly “drawn to a process for manufacturing a pharmaceutical composition for promoting insulin production;”

Group 3: Claim 9, allegedly “drawn to an agent for promoting insulin production;” and

Group 4: Claim 10, allegedly “drawn to a method of treating a patient in need comprising administering a compound for promoting insulin production.”

Office Action at Page 2.

Applicants elect Group 1, claim 7.

Applicants have added new claims 12 and 13, both of which depend from claim 7, and are directed to the elected subject matter. Support for new claims 12 and 13 is found at least on page 16, lines 5-8, and page 25, lines 9-12, of the specification. Further support can also be found in Example 6 of the specification (page 33, line 32, through page 35, line 12). No new matter has been added.

Upon entry of this amendment, claims 7, 12, and 13 are pending. Claims 1-6 and 11 are cancelled. Claims 8-10 are withdrawn.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 9, 2007

By: Jean Burke Fordis
Jean Burke Fordis
Reg. No. 32,984
Customer No. 22,852